CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 10, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of
Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the
Special Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period ended December 31, 2023 . “As Ipsen reported in February, the U.S.
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023 . “During the third quarter we saw interest income on our cash and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023 . “We were excited to see the announcement from Ipsen that the U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023 . “During the first quarter of 2023 our operating expenses remained
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022 . “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen
